नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - medroksyprogesteronacetat - tablett - 10 mg

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - sulfasalazin - enterotablett - 500 mg

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - nafarelinacetat - nesespray, oppløsning - 200 mikrog/ dose

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - noretisteron / etinyløstradiol - tablett

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 2.4 mikrog/ sprøyte

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 1.2 mikrog/ sprøyte

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - oksytetrasyklinhydroklorid / hydrokortison - salve - 30 mg/ g / 10 mg/ g

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - oksytetrasyklinhydroklorid / polymyksin b sulfat - salve - 30 mg/ g / 10000 ie/ g

नॉर्वे - नॉर्वेजियाई - Statens legemiddelverk

pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 80 mg

यूरोपीय संघ - नॉर्वेजियाई - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.